AI Needs Solid Botanical Data More than Ever
The article warns that artificial‑intelligence breakthroughs in biotech are hampered by a shortage of reliable botanical and fungal taxonomy. Most species, especially fungi, remain undescribed, leaving large language models with incomplete training data. Recent moves by Anthropic ($400 million acquisition of Coefficient Bio) and OpenAI’s life‑science investments highlight the industry’s urgency. Without solid species identification, AI‑driven drug discovery, agriculture and biosurveillance risk misclassifying harmful organisms.
Clinical Innovations and Future Directions of Nanoparticles in the Treatment of Psychiatric and Neurological Disorders
Nanoparticles are emerging as a transformative platform for treating psychiatric and neurological disorders such as depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Their physicochemical design enables crossing the blood‑brain barrier, targeted drug delivery, and enhanced imaging for early diagnosis. The...
Proline‑mediated Dichloromethyl Tagging Enables Ultra‑pure Drug Synthesis
A new method uses the amino acid proline to precisely attach dichloromethyl groups to complex molecules, enabling ultra-pure drug synthesis with built-in quality control and expanding possibilities for advanced medicine design. drugdiscovery
Compact CRISPR System Unlocks Targeted In-Body Gene Editing, with up to 90% Efficiency
Researchers at UT Austin have engineered a compact CRISPR enzyme, Al3Cas12f RKK, that fits into AAV vectors and achieves up to 90% editing efficiency in human cells. The enzyme’s small size overcomes the delivery bottleneck that limits most CRISPR systems...
![Oral Wegovy Sounds Easy, but the Reality Is More Complicated [PODCAST]](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/016265f036964b075db4a0e7e7a191dc.webp)
Oral Wegovy Sounds Easy, but the Reality Is More Complicated [PODCAST]
Oral Wegovy, the first FDA‑approved semaglutide pill, delivers rapid weight loss and metabolic improvements, but patients often experience nausea, constipation, reflux, and variable results after discontinuation. Recent pharmacovigilance data reveal a heightened signal for non‑arteritic anterior ischemic optic neuropathy, especially...
Biotech Executive, Combative Conservative Hemmati May Head CBER
The FDA is nearing a leadership transition at its Center for Biologics Evaluation and Research (CBER) as Vinay Prasad prepares to depart at month‑end. Houman David Hemmati, a biotech executive known for his combative conservative views, tops Commissioner Marty Makary’s shortlist. Several other candidates...
Designing Better Membrane Proteins by Embracing Imperfection
Scientists at the VIB‑VUB Center for Structural Biology discovered that deliberately reducing stability—through “negative design”—can improve the folding of synthetic transmembrane β‑barrel proteins. In cell‑free experiments with lipid vesicles, designs that incorporated subtle destabilizing mutations folded correctly and avoided aggregation,...
IMPORTANT REMINDER: Pfizer Whistleblower Fired Hours After Reporting “Nightmare” COVID Vaccine Trial
Brook Jackson, a senior associate at Ventavia Research Group, disclosed serious protocol breaches in Pfizer’s COVID‑19 vaccine trial, including mislabeled specimens and deliberate unblinding of participants. She reported these violations to the FDA on September 25 and was terminated by Ventavia...
Combining Ion Pumps and Click Chemistry Enables Precise Drug Release in the Body
Researchers at TU Wien have merged electronic ion pumps with click‑to‑release chemistry, creating an "iontronic click‑to‑release" system that delivers tiny trigger molecules instead of the drug itself. The triggers cleave immobilized drug linkers at the implant site, enabling precise, on‑demand...
Click Therapeutics Cuts 27% of Workforce After $50M Raise
Click Therapeutics, a digital therapeutics company, announced a $50 million Series D round led by Boehringer Ingelheim. Within days of the funding, the startup slashed more than a quarter of its workforce, eliminating roughly 27% of employees. The cuts affect both engineering...
Office of Infectious Diseases Research Activities
The FDA’s Office of Infectious Diseases outlines its antimicrobial regulatory science agenda, referencing the 2020‑2025 National Action Plan that steers U.S. efforts against antibiotic‑resistant bacteria and fungi. It announces FY26 funding opportunities through a Broad Agency Announcement, with proposals due...
These Nanotweezers Grab Thousands of Tiny Cell Packets in Seconds and Expose Their Hidden Cargo
Vanderbilt researchers led by Justus Ndukaife have unveiled interferometric electrohydrodynamic tweezers (IET), a platform that can trap and analyze thousands of nanoscale extracellular vesicles (EVs) in seconds. The system combines electrohydrodynamic flow‑based capture with label‑free interferometric imaging and Raman spectroscopy,...
From Our Perspective: The Orange Book at 40: A Valued FDA Resource Continually Enhanced by User Input
The FDA celebrated the Orange Book’s 40th anniversary, highlighting its role as the sole official source for therapeutic equivalence evaluations and reference listed drug data. The database, updated daily for generic approvals and monthly for NDA changes, underpins generic substitution,...
India Pushes Pharma Shift From Generic Volume to Biologics Innovation
Union Minister Anupriya Patel announced a $‑billion‑plus budget and regulatory reforms to steer India's pharmaceutical industry from a volume‑focused generics model toward biologics and biosimilars. The plan adds three new NIPER institutes and modernises the CDSCO, aiming to boost R&D...
Roche Secures CE Mark for Elecsys NfL Blood Test to Track MS Neuroinflammation
Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test has earned CE mark approval in Europe, enabling clinicians to monitor neuroinflammation in relapsing‑remitting multiple sclerosis with a minimally invasive assay. The move could reduce reliance on MRI and...
EU Approves Dupixent for Children 2‑11 with Chronic Spontaneous Urticaria
Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent for moderate‑to‑severe chronic spontaneous urticaria in children aged 2 to 11. The decision adds a new pediatric indication to the drug, which was already approved for adults and...
FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
The FDA has sent reminders to more than 2,200 medical‑product companies and researchers, covering over 3,000 registered trials, to file required results on ClinicalTrials.gov. An internal analysis shows that 29.6% of studies likely subject to mandatory reporting still have no...
Once More Into the Valley of Death: Navigating SBIR/STTR Funding for Tech Startups After 2025
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs were reauthorized through September 2031, adding a new Strategic Breakthrough Awards tier of up to $30 million for transformative technologies. Annual federal non‑dilutive capital now exceeds $4 billion, with cumulative...
Sex-Related Differences in Immune System Aging May Impact Disease Susceptibility
Researchers at Barcelona Supercomputing Center used single‑cell RNA sequencing on nearly 1,000 blood samples to map how immune aging differs between men and women. The analysis revealed that women experience a pronounced increase in inflammatory immune cells with age, which...
Quarterly Inactive Ingredient Database (IID) Change Log
The FDA’s Inactive Ingredient Database (IID) is updated each quarter, and the Change Log records all corrected, deleted, and Maximum Daily Exposure (MDE) replacement entries. The log spans 2020‑2026, with file sizes ranging from 21 KB to 357 KB, reflecting the volume...
Salk to Lead $41.3M ARPA-H Effort to Advance Sonogenetics Therapies
The Salk Institute secured a $41.3 million ARPA‑H award to advance sonogenetics, a technique that uses low‑intensity ultrasound to control engineered cellular proteins. Over the next five years, Salk’s Dr. Sreekanth Chalasani and a multi‑institutional team will develop ultrasound‑responsive proteins, wearable...
AACR 2026: Professional Awards Acknowledge Community’s Contributions to Cancer Research
The American Association for Cancer Research unveiled its 2026 professional award winners at the San Diego meeting (April 17‑22). Honorees span the spectrum of oncology, from James P. Allison’s seminal CTLA‑4 work to the Broad Institute’s Cancer Dependency Map team that charted...
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The FDA issued final guidance titled “Cannabis and Cannabis‑Derived Compounds: Quality Considerations for Clinical Research,” clarifying how sponsors can use both hemp and cannabis with THC levels above 0.3% in human drug trials. The guidance outlines source options—including the NIDA...
When the Data Favor Motion Preservation, How Long Does It Take for Surgeon Culture to Catch Up?
A multicenter FDA IDE trial compared the Total Posterior Spine (TOPS) facet‑replacement system with traditional transforaminal lumbar interbody fusion (TLIF) in 249 patients with grade I spondylolisthesis at L4‑5. TOPS achieved an 85% composite clinical‑success rate versus 64% for TLIF, with...
Review and Approval
The FDA approves biosimilars through an abbreviated pathway that relies on demonstrating high similarity to an existing reference biologic, rather than repeating full safety and efficacy trials. Manufacturers must provide analytical, animal, and clinical data, and the agency can waive...
DeepSeqAI Trains on Function to Future‑proof Biologics
Most AI protein tools are trained on structure. DeepSeqAI trains on function. They're running billions of experimental protein-protein interactions through their platform to map biologics against viruses, immune receptors, and the entire human proteome. The goal: candidates that hold up against...
Serum Proteomics Distinguishes Endurance versus Strength Adaptations
Adaptations to endurance vs strength training in elite athletes revealed by serum proteomics https://t.co/ii3xAiNEcT https://t.co/hBfQ0E0v9W
Advancing Fully Walkaway Automation in Genomics Workflows
SPT Labtech and the European Molecular Biology Laboratory’s GeneCore facility in Heidelberg have partnered to install the firefly®+ all‑in‑one liquid‑handling platform, aiming to deliver fully walkaway automated genomics workflows. The system combines pipetting, dispensing, incubation and shaking, and will run...
Why Anthropic Chose Coefficient Bio Over Bigger Rivals?
Reading up on the Coefficient Bio deal. I totally get the industrial logic around why Anthropic should care about drug discovery. But why this particular company? There's lots of more scaled players doing this. Can anyone educate me? https://t.co/akFVmRUaYw
Vivatides Therapeutics Raises $54M for RNA Expansion
Vivatides Therapeutics announced a $54 million Series A round, led by Qiming Venture Partners and backed by several other investors. The funding will accelerate its proprietary extrahepatic delivery platform, designed to transport RNA molecules such as siRNA and antisense oligonucleotides beyond the...
Loyal Raises $100 Million: Dog Longevity Drugs Targeting IGF-1 and PPAR Pathways
Loyal, a veterinary biotech firm, announced a $100 million financing round to advance its canine longevity platform. The company targets the IGF‑1 and PPAR pathways to develop drugs that extend the lifespan of senior and large‑breed dogs. It has secured conditional...
Minimally-Invasive Stenting Effectively Treats Painful Post-Thrombotic Syndrome
Washington University researchers led the NIH‑funded C‑TRACT trial, showing that minimally invasive venous stenting markedly improves outcomes for patients with post‑thrombotic syndrome. Among 225 participants with severe disease, stent plus standard therapy reduced the persistence of severe syndrome to 40%...
Evidence for Retrotransposon Suppression to Reduce Biological Age in Humans
Researchers evaluated two FDA‑approved nucleoside reverse transcriptase inhibitor (NRTI) regimens in healthy adults to see if they could blunt age‑related epigenetic drift. Over 12 weeks, the emtricitabine/tenofovir‑alafenamide (FTC/TAF) combo lowered multiple DNA‑methylation clocks, including DunedinPACE and PhenoAge, and reduced inflammatory...
TANGENT Phase 3 Study Meets Primary and Secondary Endpoints, SynOx Reports
SynOx Therapeutics reported that its Phase 3 TANGENT study of emactuzumab met both primary and secondary endpoints in tenosynovial giant cell tumor (TGCT). The five‑dose, eight‑week regimen achieved statistically significant RECIST responses and tumor volume reductions at six months. Patients also...
Powering a Smarter, Scalable Future for Bioprocessing
Yokogawa introduced Bio Pilot, a vendor‑agnostic platform that integrates equipment, data and workflows across both upstream and downstream bioprocessing. The solution replaces fragmented, manual operations with real‑time analytics, model‑predictive control and a no‑code workflow editor that automates SOPs. Early deployments...
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
F.D.A. Calls on Drug Developers to Publish Missing Data From Thousands of Trials
The FDA announced it has dispatched more than 2,200 letters to drug makers, device manufacturers and researchers, demanding the publication of clinical‑trial results that remain absent from ClinicalTrials.gov. An internal analysis shows roughly 30 % of studies under FDA review have...
Busy Biotech Day Highlights Promising Advances and Insightful Commentary
As usual, excellent summary by @ldtimmerman @timmermanreport of busy and promising biotech news day - as always delivered w insight and heart (especially thoughtful comments re: revmed drug in context of poignant recent @BenSasse interview)
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
ROIS Expands US Injectable Manufacturing Capacity
ROIS has completed the acquisition of a 370,000‑square‑foot injectable manufacturing facility in Phoenix, Arizona, adding high‑potent fill/finish and lyophilization capabilities for biologics and antibody‑drug conjugates (ADCs). The site already holds FDA, EMA and Japanese regulatory approvals, enabling immediate support for...
FDA Narrows in on Search for New Biologics and Vaccines Leader
The U.S. Food and Drug Administration is close to naming a new director for its Center for Biologics Evaluation and Research (CBER), ending the turbulent tenure of Vinay Prasad. Sources say the leading candidate is Dr. Susan K. Lee, a...
October - December 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System...
The FDA’s Adverse Event Reporting System (FAERS) prompted a wave of labeling revisions between 2023 and 2025, adding new safety warnings to dozens of drugs. Notable changes include hypersensitivity alerts for cabotegravir injectables, fecal incontinence risks for several atypical antipsychotics,...
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
The FDA issued a second complete response letter rejecting Replimune’s biologics license application for RP1 combined with nivolumab in advanced melanoma, citing insufficient data to isolate RP1’s contribution. Replimune’s CEO warned of job cuts and a scale‑back of U.S. manufacturing....
Spinal Elements Wins FDA Clearance for Ventana A ALIF System, Expands 3D-Printed Spine Portfolio
Spinal Elements has secured FDA 510(k) clearance for its Ventana A anterior lumbar interbody fusion (ALIF) system, the latest addition to its 3D‑printed titanium spine portfolio. The company reports that the first U.S. cases have already been completed, demonstrating early...
Kailera Therapeutics (KLRA) IPO Deck
Kailera Therapeutics (KLRA) is preparing an initial public offering to fund its GLP‑1‑based obesity drug platform, which includes both injectable and oral candidates. The company’s pipeline spans multiple clinical stages, from early‑phase studies to late‑stage trials, positioning it to capture...
A Novel Approach To The Treatment Of Antibiotic Resistant Infections
Researchers have engineered microscopic, cell‑like particles that hunt drug‑resistant bacteria while sparing healthy microbes. The particles use protein‑based recognition to bind unique bacterial markers and deliver toxic proteins or bactericidal chemicals in a two‑step process. Laboratory tests showed a single...
NHS Improves Genetic Testing for Minority Ethnic Cancer Patients
The NHS has expanded its pre‑chemotherapy genetic screening to include a fifth DPYD gene variant that is more common among Black and minority‑ethnic patients. Previously, tests only covered four variants prevalent in white European populations, leaving many patients at risk...
Robust Bio Tools Demand Exhaustive Edge‑Case Testing
Hardest part of making bio tools is the endless testing of edge cases, to make sure that sequences are holy, circular permutation is accounted for, degenerate bases are considered, etc. To make robust code worthy of wetlab requires attention. I'm...
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
UniQure Investors Face April 13 Deadline to Lead Securities‑fraud Lawsuit
UniQure N.V. shareholders who purchased ordinary shares between September 24 and October 31, 2025, have until April 13, 2026 to file a motion to serve as lead plaintiff in a securities‑fraud class action. The lawsuit, filed by Rosen Law Firm,...